(PEN) Penumbra, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PEN) Penumbra, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Penumbra, Inc. BCG Matrix is a company-specific strategic tool used to assess how its products or business units may fall across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Indigo System
Indigo System is Penumbra, Inc.’s large-bore aspiration thrombectomy platform for vascular intervention, sold through its direct sales force and distributors in global markets. In 2025, the acute clot-removal segment stayed in a high-growth lane as thrombectomy demand rose across stroke and peripheral use cases. That mix supports Star status: strong growth, high clinical need, and broad commercial reach.
Penumbra System
Penumbra System stays a Star because mechanical thrombectomy is core to Penumbra, Inc.'s neuro and peripheral mix, with branded tools used in stroke and clot removal. Acute ischemic stroke makes up about 87% of all strokes, and the U.S. sees roughly 795,000 strokes a year, supporting demand. As care shifts toward faster clot retrieval, the platform's growth profile stays strong.
Penumbra RED
Penumbra RED sits in Penumbra, Inc.’s thrombectomy lineup and rides the same acute clot-removal demand as other aspiration tools. Penumbra, Inc. posted about $1.1 billion in 2025 revenue, up roughly 16% year over year, and that scale supports RED’s share. The company’s broad U.S. and international sales reach helps keep the brand in front of stroke and PE buyers.
ACE
ACE is Penumbra, Inc.'s aspiration thrombectomy brand for vascular intervention, and it sits in a hospital category that keeps expanding as stroke and clot-treatment volumes rise. Penumbra said 2025 revenue was about $1.2 billion, with growth driven by thrombectomy demand, which supports a Star read: high market growth and strong competitive position.
- Used in vascular intervention
- Fits a growing hospital category
- Star profile: growth plus share
JET
JET is another branded thrombectomy device in Penumbra, Inc.'s portfolio, and it fits a Star in the BCG Matrix because it plays in a high-need interventional market that is still gaining adoption. Penumbra reported 2025 net sales of about $1.1 billion, showing the franchise is already meaningful but still has room to expand.
- High clinical need supports growth
- Adoption still needs education
- Placement support remains key
That means JET needs active promotion, training, and hospital placement support to keep winning share as the thrombectomy category expands.
Penumbra’s Thrombectomy Stars Are Driving Fast Growth
Penumbra, Inc.’s Stars are its thrombectomy franchises: Indigo System, Penumbra System, RED, ACE, and JET. These brands sit in fast-growing stroke and clot-removal markets, backed by 2025 revenue of about $1.1 billion to $1.2 billion and roughly 16% year-over-year growth. Strong clinical demand and broad hospital reach support their Star position.
| Brand | Star signal |
|---|---|
| Indigo | Large-bore thrombectomy growth |
| Penumbra System | Core stroke demand |
| RED | Clot-removal adoption |
| ACE and JET | Expanding interventional use |
What is included in the product
Detailed Word Document
Penumbra, Inc. BCG Matrix: maps its product portfolio by growth and share to flag invest, hold, and divest priorities.
Editable Excel File
Printable Penumbra, Inc. BCG Matrix view that quickly highlights pain points and growth priorities for decision-makers
Reference Sources
Penumbra, Inc. Reference Sources give a credible audit trail that speeds due diligence and supports confident decisions.
Cash Cows
Penumbra SMART Coil
Penumbra SMART Coil is a neurovascular coil used to treat aneurysms and lesions, and it fits a mature, repeat-use market with steady procedure demand. Penumbra reported about $1.1 billion in FY2024 net sales, showing the scale behind this franchise. Mature use, recurring hospital adoption, and established clinical need make SMART Coil a cash generator.
Penumbra Coil 400
Penumbra Coil 400 is a detachable coil in Penumbra, Inc.'s embolization portfolio, and that mature coil market is less growth-driven than thrombectomy. That makes it a Cash Cow candidate in the BCG Matrix: lower growth, but steady demand and repeat use support stable cash flow. It helps fund higher-growth bets in the neurovascular mix.
Ruby Coil
Ruby Coil fits Cash Cow status: it is a peripheral embolization coil used for vessel occlusion in a mature interventional category. Penumbra's FY2025 business still leaned on recurring hospital demand, where repeat procedure use and standard purchasing drive steady cash flow rather than fast growth. Mature coil adoption and stable clinical need make Ruby Coil a low-drama, high-cash contributor.
Neuron and Neuron MAX
Neuron and Neuron MAX fit Cash Cows because they are mature intracranial access systems used to reach target vessels in routine neurointervention. Penumbra, Inc.’s broad installed base supports repeat use and steady revenue, even as growth slows in newer lines. Access hardware stays a high-volume, low-drama category, so it keeps cash flowing.
- Mature, high-volume access hardware
- Repeat use supports steady revenue
BENCHMARK and BMX96
BENCHMARK and BMX96 fit a Cash Cow profile because Penumbra uses them in routine neurovascular access and support workflows, where repeat procedures drive steady reorder demand. In 2024, Penumbra reported net sales of about $1.1 billion, and this mature category benefits from high procedural frequency and low replacement churn.
- Repeat-use neurovascular access tools
- Stable demand from routine workflows
- Supports recurring hospital purchasing
- Cash generation over fast growth
Penumbra’s Cash Cows: Steady Sales From Coils and Access Tools
Penumbra’s Cash Cows are mature coils and access tools: SMART Coil, Coil 400, Ruby Coil, Neuron/Neuron MAX, and BENCHMARK/BMX96. Penumbra reported about $1.1 billion in FY2024 net sales, and FY2025 still leaned on repeat hospital demand in these low-growth categories. That mix points to steady cash, not fast growth.
| Cash Cow | Why |
|---|---|
| Coils | Repeat use |
| Access tools | Stable reorder demand |
Get Your Copy
Penumbra, Inc. Reference Sources
You’re previewing the exact Penumbra, Inc. BCG Matrix document you’ll receive after purchase. No demo pages or placeholder content—just the full, ready-to-use report. It’s formatted for quick review, strategic planning, and professional presentation. Once purchased, the same file is available for immediate download.
Dogs
LANTERN microcatheters
LANTERN microcatheters fit the Dogs side of Penumbra, Inc.'s BCG Matrix because microcatheters sit in a crowded, price-driven support-device market with low product separation. Penumbra's 2024 net sales were about $1.1 billion, but it does not break out LANTERN revenue, which signals limited standalone scale. In catheter segments, small share gains rarely offset thin margins and heavy competition.
DDC
DDC sits in Penumbra, Inc.'s mature catheter-access niche, where crowded rivals and slower growth make it a Dog in BCG terms. Penumbra's FY2025 revenue was about $1.2B, but this category still looks like low-share, low-return capital. Unless DDC gains clear share, its economics stay weak versus faster-growing thrombectomy platforms.
PX SLIM
PX SLIM sits in Penumbra, Inc.'s neurovascular access stack as a support catheter, a line where product overlap is common across medtech suppliers. In a mature, low-differentiation category, small-share SKUs usually act like Dogs because they face price pressure and limited upside. Penumbra reported about $1.2 billion in 2024 net sales, so this kind of niche line likely matters more for fill-in coverage than for growth.
Packing Coil
Packing Coil sits in a mature embolization niche, so it behaves more like a steady, low-growth product than a BCG star. Penumbra does not break out Packing Coil revenue, but its coil business is small versus 2024 company net sales of $1.1 billion, so limited share would add little cash. Commodity-like coil markets also face price pressure and slow unit growth.
- Peripheral occlusion coil
- Mature embolization category
- Low growth, low differentiation
- Limited cash if share stays small
Packing Coil LP
Packing Coil LP fits the Dog box: it is a low-profile coil for vessel occlusion in a mature, crowded market, so growth is usually slow and share gains are hard. Penumbra, Inc. has said its embolization and access franchise faces strong competition, which supports the low-growth, modest-share profile. In BCG terms, this product is more about defending a niche than driving scale.
- Low-profile coil for vessel occlusion
- Established market, heavy competition
- Low growth, modest share
- Classic Dog profile
Penumbra’s “Dogs”: Low-Share Products in Crowded Markets
Dogs in Penumbra, Inc.'s BCG Matrix are small, mature support products like LANTERN, DDC, PX SLIM, and Packing Coil. They sit in crowded, price-led markets with low differentiation, so share gains are hard and cash use can outweigh return. Penumbra's FY2025 revenue was about $1.2B, but these lines are not broken out, which points to limited standalone scale.
| Product | Dog signal | Latest data |
|---|---|---|
| LANTERN | Low share, crowded catheter market | FY2025 revenue about $1.2B companywide |
| Packing Coil | Mature embolization niche | No segment revenue disclosed |
Question Marks
Artemis Neuro Evacuation Device
Artemis Neuro Evacuation Device is a neurosurgical aspiration tool for removing tissue and fluid, so it sits next to Penumbra, Inc.'s core thrombectomy base rather than inside it. That makes it a Question Mark: the addressable market is attractive, but share is still unproven and adoption is early. If clinical use scales, it could gain from the same 2025 medtech capital base that backed Penumbra's broader growth.
Real Immersive System
Real Immersive System is a computer-based immersive therapy platform, so it sits outside Penumbra's device-led core and fits the Question Mark box. In 2025, Penumbra reported net sales of about $1.1 billion, but this category is still early-stage, with adoption and market share only starting to build. Its upside is real, but it needs more proof before it can move toward a Star.
Penumbra ENGINE
Penumbra ENGINE fits Question Mark status because it supports aspiration-based thrombectomy hardware in a fast-growing segment, but Penumbra is still building share around the core system. Penumbra’s latest annual filings show company revenue above $1 billion, so the platform has scale behind it, yet adoption still needs proof. Hardware can expand fast, but the payoff is not settled yet.
POD400
POD400 is a detachable embolic device for peripheral vessel occlusion, so it fits Penumbra, Inc. as a Question Mark: the peripheral embolization market is growing, but category share is still contested. Penumbra, Inc. reported 2025 revenue of about $1.23B, up 13% year over year, but it does not break out POD400 sales.
- Growth tailwind: peripheral embolization
- Share remains hard-fought
- Needs proof of adoption
PAC400
PAC400 is Penumbra, Inc.'s detachable embolic coil system in the peripheral space, and it sits in a growing but crowded niche where Penumbra booked about $1.1 billion in net sales in 2024. The product can benefit from more peripheral embolization cases, but it still needs clear share gains against better-known rivals. Until adoption scales, PAC400 remains a Question Mark.
- Peripheral use case is expanding.
- Competition is still intense.
- Share must improve to re-rate.
Penumbra’s New Bets Show Promise, but the Core Still Carries
Penumbra, Inc.'s Question Marks are newer bets with growth potential but limited proof of share. Artemis, Real Immersive System, Penumbra ENGINE, POD400, and PAC400 all sit in expanding niches, yet 2025 revenue of about $1.23B still shows the core is carrying the portfolio while adoption scales.
| Product | Fit | Signal |
|---|---|---|
| Artemis | Question Mark | Early adoption |
| Real Immersive System | Question Mark | New category |
| PENUMBRA ENGINE | Question Mark | Share still building |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.